Increased oncogenic microRNA-18a expression in the peripheral blood of patients with prostate cancer: A potential novel non-invasive biomarker

Oncology Letters

Volumn 11, Issue 2, 2016, Pages 1201-1206

  Al Kafaji, Ghada ^a   Al Naieb, Ziad Tariq ^a   Bakhiet, Moiz ^a  

^a ARABIAN GULF UNIVERSITY   (Bahrain)

Author keywords

Benign prostatic hyperplasia; Biomarker; microRNA; Peripheral blood miR 18; Prostate cancer

Indexed keywords

MICRORNA; MICRORNA 18A; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; MALE; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION; RNA EXTRACTION; SEQUENCE ANALYSIS; WESTERN BLOTTING;

EID: 84954348477     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.4014     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Mettlin C, Lee F, Drago J and Murphy GP: The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 67: 2949-58, 1991.
3. Nadler RB, Humphrey PA, Smith DS, Catalona WJ and Ratliff TL: Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 154: 407-413, 1995.
4. Brawer MK: Prostate-specific antigen: Current status. CA Cancer J Clin 49: 264-281, 1999.
5. Gretzer MB and Partin AW: PSA markers in prostate cancer detection. Urol Clin North Am 30: 677-686, 2003.
6. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism and function. Cell 116: 281-297, 2004.
7. Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell 11: 441-450, 2006.
8. Ha TY: MicroRNAs in Human diseases: From cancer to cardiovascular disease. Immune Netw 11: 135-154, 2011.
9. Kent OA and Mendell JT: A small piece in the cancer puzzle: MicroRNAs as tumor suppressors and oncogenes. Oncogene 25: 6188-6196, 2006.
10. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005.
11. Ozen M, Creighton CJ, Ozdemir M and Ittmann M: Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27: 1788-1793, 2008.
12. Dews M, Homayouni A, Yu D, et al: Augmentation of tumor angiogenesis by a Myc activated microRNA cluster. Nat Genet 38: 1060-1065, 2006.
13. Hayashita Y, Osada H, Tatematsu Y, et al: A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 65: 9628-9632, 2005.
14. Yao Y, Suo AL, Li ZF, et al: MicroRNA profiling of human gastric cancer. Mol Med Rep 2: 963-970, 2009.
15. Ayala de la Peña F, Kanasaki K, Kanasaki M, Tangirala N, Maeda G and Kalluri R: Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. J Biol Chem 286: 20778-20787, 2011.
16. Hsu TI, Hsu CH, Lee KH, et al: MicroRNA-18a is elevated in prostate cancer and promotes tumorigenesis through suppressing STK4 in vitro and in vivo. Oncogenesis 3: e99, 2014.
17. Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
18. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y and Ochiya T: Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 285: 17442-17452, 2010.
19. Zheng H, Zhang L, Zhao Y, et al: Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One 8: e77853, 2013.
20. Chen X, Ba Y, Ma L, et al: Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006, 2008.
21. Wang GK, Zhu JQ, Zhang JT, et al: Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31: 659-666, 2010.
22. Roth P, Wischhusen J, Happold C, Chandran PA, Hofer S, Eisele G, Weller M and Keller A: A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem 118: 449-457, 2011.
23. Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, Lux MP, Jud SM, Hartmann A, Hein A, et al: Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One 7: e29770, 2012.
24. Meder B, Keller A, Vogel B, Haas J, Sedaghat-Hamedani F, Kayvanpour E, Just S, Borries A, Rudloff J, Leidinger P, et al: MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol 106: 13-23, 2011.
25. Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, Wendschlag A, Giese N, Tjaden C, Ott K, et al: Toward the blood-borne miRNome of human diseases. Nat Methods 8: 841-843, 2011.
26. Median-Villaamil V, Martinez-Breijo S, Portela-Pereira P, Quindós-Varela M, Santamarina-Cainzos I, Antón-Aparicio LM and Gómez-Veiga F: Circulating MicroRNAs in blood of patients with prostate cancer. Actas Urol Esp 38: 633-639, 2014 (In English, Spanish).
27. Gleason DF, Mellinger GT: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111: 58-64, 1974.
28. Gleason DF: Histologic grading of prostate cancer: A perspective. Hum Pathol 23: 273-279, 1992.
29. th edition. Wiley-Liss, New York, NY, USA, pp 184-187, 2002.
30. Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108, 2008.
31. Minoo P, Zlobec I, Baker K, Tornillo L, Terracciano L, Jass JP and Lugli A: Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer. Mod Pathol 20: 331-338, 2007.
32. Zhou D, Conrad C, Xia F, Park J, Payer B, Yin Y, Lauwers GY, Thasler W, Lee JT, Ayruch J and Bardeesy N: Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16: 425-438, 2009.
33. Morimura R, Komatsu S, Ichikawa D, et al: Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer 105: 1733-1740, 2011.
34. Luo X, Stock C, Burwinkel B and Brenner H: Identification and evaluation of plasma MicroRNAs for early detection of colorectal cancer. PLoS One 8: e62880, 2013.
35. Hirajima S, Komatsu S, Ichikawa D, Takeshita H, Konishi H, Shiozaki A, Morimura R, Tsujiura M, Nagata H, Kawaguchi T, et al: Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer 108: 1822-1829, 2013.
36. Hoffman RM, Gilliland FD, Adams-Cameron M, Hunt WC and Key CR: Prostate-specific antigen testing accuracy in community practice. BMC Fam Pract 3: 19, 2002.